Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,306 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Growth Disorder Clear all
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 4, 2026, 3:55 PM EDT
Completed No phase listed Observational

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lifestyle Intervention in Preparation for Pregnancy (LIPP)

NCT03146156
View directory record Official record
Conditions
Obesity, Lifestyle-related Condition, Macrosomia, Fetal
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 4, 2026, 3:55 PM EDT
Terminated Phase 1 Interventional

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

NCT00783172
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Opioid Growth Factor (OGF)
Drug · Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Allentown, Pennsylvania • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

NCT00570011
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Sep 4, 2026, 3:55 PM EDT
Completed No phase listed Observational Results available

Acromegaly Treatment Quality of Life Study

NCT01732406
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Androgenetic Alopecia in Males and Females

NCT01437163
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
Device
Lead sponsor
Apira Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326
View directory record Official record
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 4, 2026, 3:55 PM EDT
Terminated Not applicable Interventional

Reducing Insulin, Growth Hormones, and Tumors

NCT03785808
View directory record Official record
Conditions
Diet Modification, Lung Cancer
Interventions
Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 4, 2026, 3:55 PM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 2 Interventional

Growth Hormone to Increase Immune Function in People With HIV

NCT00071240
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin (recombinant human growth hormone)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2009 · Synced Sep 4, 2026, 3:55 PM EDT
Completed No phase listed Observational

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913
View directory record Official record
Conditions
Urothelial Cancer, Receptors, Fibroblast Growth Factor
Interventions
Archival Tumor Tissue Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Iron Source on the Growth of Enteric Pathogens

NCT05314062
View directory record Official record
Conditions
Iron-deficiency, Iron Deficiency Anemia, Iron Deficiency Anemia Treatment
Interventions
FeSO4, Ao iron
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

DHA Supplementation for Lactating Mothers

NCT01732874
View directory record Official record
Conditions
Docosohexaenoic Acid Supplementation of Mothers to
Interventions
Expecta 200 mg, Expecta 1 gram
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 4, 2026, 3:55 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 3:55 PM EDT
Terminated Phase 2 Interventional

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

NCT00005987
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cyclophosphamide, dexamethasone, etoposide, filgrastim, mitoxantrone hydrochloride, recombinant interferon alfa, sargramostim, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 4, 2026, 3:55 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 4, 2026, 3:55 PM EDT
Terminated Phase 4 Interventional Results available

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

NCT00742157
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Growth Hormone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 78 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

NCT02404870
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Canagliflozin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Not applicable Interventional Results available

Neurodevelopmental and Growth Outcomes of Early, Aggressive Protein Intake in Very Low Birthweight Infants

NCT01860573
View directory record Official record
Conditions
Prematurity
Interventions
Amino acids
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
Up to 18 Hours
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 4, 2026, 3:55 PM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 4, 2026, 3:55 PM EDT
Active, not recruiting No phase listed Observational

X-linked Hypophosphatemia Disease Monitoring Program

NCT03651505
View directory record Official record
Conditions
X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions
No intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 3:55 PM EDT
Terminated No phase listed Observational

Monitoring Growth of Preterm Infants

NCT01869153
View directory record Official record
Conditions
Prematurity
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 4, 2026, 3:55 PM EDT